A Phase II Pharmacodynamic Study of Preoperative Figitumumab in Patients with Localized Prostate Cancer
Clinical Cancer Research, 05/31/2012
Chi KN et al. – Figitumumab is biologically active in prostate cancer. Prostate–specific antigen (PSA) declines in treatment–naive patients were observed, potentially mediated by insulin–like growth factor 1 receptor (IGF–IR) effects on androgen receptor expression. These results support the clinical relevance of IGF–IR signaling in prostate cancer and justify further clinical trials.